Sorted by Relevance | Sort by Date
Search Results for performance+enhancing+drugs
Genzyme's Cerezyme shortage may cause more problems than anticipated
Pharmaceutical drugmaker Genzyme (NASDAQ: GENZ), based in Cambridge, Massachusetts, specializes in creating drugs for rare diseases. Despite the small market, the Orphan Drug Act gives the company tax credits and enhanced patent protection, virtually ...
NY digs deeper into Vytorin study
The Wall Street Journal reports that Attorney General Andrew Cuomo has launched an investigation into both Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP).
The New York AG is concerned that both companies may have "deliberately concealed" negative ...
Baseball needs to discipline players named in the Mitchell Report (update)
Baseball Commissioner Bud Selig needs to discipline the players named in the Mitchell Report on steroid use that's set to be released today. It's not only the right thing to do for the game's future but it's the best way to safeguard the game's ...
Money Losers of 2007: Marion Jones is last out of the blocks
Could there be any worse fate for an Olympic level athlete than to be stripped of their statistics and medals? Yes, there could be worse things. Just ask former Olympic track star Marion Jones which is worse, losing your medals or being forced to ...
Having hobbies is good for job performance
When Bear Stearns (NYSE: BSC) CEO James Cayne was golfing, playing bridge and, allegedly, smoking weed during the subprime meltdown, there was universal outrage -- How could the man at the top be off indulging in hobbies while Rome was burning? The ...
America is ready to forgive steroid users -- if they'll admit it
Yesterday, I praised Adam Piatt for his admission of steroid use and efforts to assist former Senator George Mitchell in his efforts to investigate performance enhancing drug use in professional baseball. I wrote that "Hopefully the media will treat ...
Barry Bonds indicted for perjury and obstruction of justice
Barry Bonds was indicted Thursday for perjury and obstruction of justice. It may very well be that the all-time home run record holder will be spending a lot more time in court rooms and with attorneys than playing baseball next season.
"A ...
Eli Lilly to restructure, bet on drug portfolio
Pharmaceutical company Eli Lilly & Co. (NYSE: LLY) is planning to cut 5,500 jobs over the next few years and reorganize into five business units. The company is looking to reduce costs and accelerate how long it takes new drugs to get to ...
Gilead (GILD): New potential in 4-in-1 HIV drug
"Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.
The contributing editor to Personal Finance explains, "Already the market leader in ...
Delcath jumps 18% as its chemotherapy agent gets orphan drug status
Delcath Systems Inc. (NASDAQ: DCTH), which in pre-market trading shot up 48%, closed the trading session up 18% to close at $3.60 after the FDA granted its chemotherapy agent doxorubicin, used primarily for live cancer an orphan drug status. The ...
Medivation (MDVN): Drug firm targets Alzheimer's
For speculative investors aware of the risks associated with a development stage drug company, Karim Rahemtulla looks to Medivation (NASDAQ: MDVN), a play on development of a drug to treat Alzheimer's.
In his Xcelerated Profits Report, the advisor ...
Purdue Pharma fights OxyContin abuse
When Purdue Pharma introduced its pain killer OxyContin to the market back in 1997 the drug was hailed as a savior for seriously ill patients. Unfortunately, what makes the drug so effective also makes it highly addictive, and easily abused. Purdue ...
FDA raises issues with Genzyme's leukemia drug study
The U.S. Food and Drug Administration (FDA) has some questions for Genzyme Corp. (NASDAQ: GENZ) regarding trial data for its leukemia drug, Clolar. Because Genzyme didn't follow the FDA's recommendations in conducting its main study of Clolar, the ...
Turnaround time for drug stocks? 10 top picks
"You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.
Here, in his industry-leading The ...
Taking a $752,467 stand: Bonds' ball to be branded
During the past week or so, fashion designer Marc Ecko has been tabulating votes to decide what to do with Barry Bonds' 756th home-run ball. The three choices offered in an online poll were: Bestow It, Brand It, Banish It. The fans have spoken, and ...
The week in preview: No turkey earnings from Tyson, Hormel, Cracker Barrel ...
Comfort Zone Investing: Intel is saying something ... can you hear it?
Twitter finally reveals revenue ambition, wants to be Google -- but not yet
